Skip to main content Help with accessibility Skip to main navigation

Eluxadoline

Indication

Treating irritable bowel syndrome with diarrhoea (NICE TA471)

MHRA Drug Safety Update - Eluxadoline (Truberzi▼): risk of pancreatitis; do not use in patients who have undergone cholecystectomy or in those with biliary disorders

 

Red

Brand:

Truberzi®

Nice TA:

471

Commissioning responsibility:

CCG

PbR excluded:

No

BNF chapter:
Gastro-intestinal system

Background

Eluxadoline is recommended as an option for treating irritable bowel syndrome with diarrhoea in adults, only if:
  • the condition has not responded to other pharmacological treatments (for example, antimotility agents, antispasmodics, tricyclic antidepressants) or
  • pharmacological treatments are contraindicated or not tolerated, and
  • it is started in secondary care.
Stop eluxadoline at 4 weeks if there is inadequate relief of the symptoms of irritable bowel syndrome with diarrhoea.

Recommendation

LSCMMG Recommendation:

Red

Reason for decision:

Specialist medicine

Supporting documents:

Decisions of Lancashire local decision making groups

BwD
BP
CSR
EL
FW
GP
MB
WL
Red
Red
Red
Red
Red
Red
Red
Red
What do the colours mean?

Last Updated: 01 - Apr - 2018